Geoffrey S. Ibbott

Geoffrey S. Ibbott

Auto-generated profile, based on publicly available information

Geoffrey S. Ibbott

MD Anderson Cancer Center, Houston, TX

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2016 in Medical Physics
Verified
Journal Article
Open access
PDF file
MHM. Saiful Huq
M. Saiful Huq
BFBenedick A. Fraass
Benedick A. Fraass
PDPeter B. Dunscombe
Peter B. Dunscombe
JGJohn P. Gibbons
John P. Gibbons
GIGeoffrey S. Ibbott
Geoffrey S. Ibbott
EYEllen D. Yorke
Ellen D. Yorke
The increasing complexity of modern radiation therapy planning and delivery challenges traditional prescriptive quality management (QM) methods, such as many of those included in guidelines published by organizations such as the AAPM, ASTRO, ACR, ESTRO, and IAEA. These prescriptive guidelines have traditionally focused on monitoring all aspects of the functional performance of radiotherapy (RT) equipment by comparing parameters against tolerances set at strict but achievable values. Many errors that occur in radiation oncology are not due to failures in devices and software; rather they are failures in workflow and process. A systematic understanding of the likelihood and clinical impact of possible failures throughout a course of radiotherapy is needed to direct limit QM resources efficiently to produce maximum safety and quality of patient care. Task Group 100 of the AAPM has taken a broad view of these issues and has developed a framework for designing QM activities, based on estimates of the probability of identified failures and their clinical outcome through the RT planning and delivery process. The Task Group has chosen a specific radiotherapy process required for “intensity modulated radiation therapy (IMRT)” as a case study. The goal of this work is to apply modern risk‐based analysis techniques to this complex RT process in order to demonstrate to the RT community that such techniques may help identify more effective and efficient ways to enhance the safety and quality of our treatment processes. The task group generated by consensus an example quality management program strategy for the IMRT process performed at the institution of one of the authors. This report describes the methodology and nomenclature developed, presents the process maps, FMEAs, fault trees, and QM programs developed, and makes suggestions on how this information could be used in the clinic. The development and implementation of risk‐assessment techniques will make radiation therapy safer and more efficient.

1 August 2016 in Medical Physics
Verified
Journal Article
Closed access
DOD. J. O'BRien
D. J. O'BRien
DRD. A. Roberts
D. A. Roberts
GIG. S. Ibbott
G. S. Ibbott
GSG. O. Sawakuchi
G. O. Sawakuchi

9 April 1999 in Medical Physics
Verified
Journal Article
Closed access
JWJeffrey F. Williamson
Jeffrey F. Williamson
BCBert M. Coursey
Bert M. Coursey
LDLarry A. DeWerd
Larry A. DeWerd
WHWilliam F. Hanson
William F. Hanson
RNRavinder Nath
Ravinder Nath
GIGeoffrey Ibbott
Geoffrey Ibbott

1 June 2016 in Medical Physics
Verified
Journal Article
Open access
PDF file
RNRavinder Nath
Ravinder Nath
MRMark J. Rivard
Mark J. Rivard
LDLarry A. DeWerd
Larry A. DeWerd
WDWilliam A. Dezarn
William A. Dezarn
HHH. Thompson Heaton
H. Thompson Heaton
JVJack L. M. Venselaar
Jack L. M. Venselaar
Although a multicenter, Phase III, prospective, randomized trial is the gold standard for evidence‐based medicine, it is rarely used in the evaluation of innovative devices because of many practical and ethical reasons. It is usually sufficient to compare the dose distributions and dose rates for determining the equivalence of the innovative treatment modality to an existing one. Thus, quantitative evaluation of the dosimetric characteristics of innovative radiotherapy devices or applications is a critical part in which physicists should be actively involved. The physicist's role, along with physician colleagues, in this process is highlighted for innovative brachytherapy devices and applications and includes evaluation of (1) dosimetric considerations for clinical implementation (including calibrations, dose calculations, and radiobiological aspects) to comply with existing societal dosimetric prerequisites for sources in routine clinical use, (2) risks and benefits from a regulatory and safety perspective, and (3) resource assessment and preparedness. Further, it is suggested that any developed calibration methods be traceable to a primary standards dosimetry laboratory (PSDL) such as the National Institute of Standards and Technology in the U.S. or to other PSDLs located elsewhere such as in Europe. Clinical users should follow standards as approved by their country's regulatory agencies that approved such a brachytherapy device. Integration of this system into the medical source calibration infrastructure of secondary standard dosimetry laboratories such as the Accredited Dosimetry Calibration Laboratories in the U.S. is encouraged before a source is introduced into widespread routine clinical use. The American Association of Physicists in Medicine and the Groupe Européen de Curiethérapie‐European Society for Radiotherapy and Oncology (GEC‐ESTRO) have developed guidelines for the safe and consistent application of brachytherapy using innovative devices and applications. The current report covers regulatory approvals, calibration, dose calculations, radiobiological issues, and overall safety concerns that should be addressed during the commissioning stage preceding clinical use. These guidelines are based on review of requirements of the U.S. Nuclear Regulatory Commission, U.S. Department of Transportation, International Electrotechnical Commission Medical Electrical Equipment Standard 60601, U.S. Food and Drug Administration, European Commission for CE Marking (Conformité Européenne), and institutional review boards and radiation safety committees.

20 December 2004 in Medical Physics
Verified
Journal Article
Closed access
SCSang Hyun Cho
Sang Hyun Cho
OVOleg N. Vassiliev
Oleg N. Vassiliev
SLSeungsoo Lee
Seungsoo Lee
HLH. Helen Liu
H. Helen Liu
GIGeoffrey S. Ibbott
Geoffrey S. Ibbott
RMRadhe Mohan
Radhe Mohan

20 August 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JMJeff Michalski
Jeff Michalski
KWKathryn A. Winter
Kathryn A. Winter
BPBradley R. Prestidge
Bradley R. Prestidge
MSMartin G. Sanda
Martin G. Sanda
MAMahul Amin
Mahul Amin
HSHoward M. Sandler
Howard M. Sandler
PURPOSE: To determine whether addition of external beam radiation therapy (EBRT) to brachytherapy (BT) (COMBO) compared with BT alone would improve 5-year freedom from progression (FFP) in intermediate-risk prostate cancer.METHODS: Men with prostate cancer stage cT1c-T2bN0M0, Gleason Score (GS) 2-6 and prostate-specific antigen (PSA) 10-20 or GS 7, and PSA < 10 were eligible. The COMBO arm was EBRT (45 Gy in 25 fractions) to prostate and seminal vesicles followed by BT prostate boost (110 Gy if 125-Iodine, 100 Gy if 103-Pd). BT arm was delivered to prostate only (145 Gy if 125-Iodine, 125 Gy if 103-Pd). The primary end point was FFP: PSA failure (American Society for Therapeutic Radiology and Oncology [ASTRO] or Phoenix definitions), local failure, distant failure, or death.RESULTS: Five hundred eighty-eight men were randomly assigned; 579 were eligible: 287 and 292 in COMBO and BT arms, respectively. The median age was 67 years; 89.1% had PSA < 10 ng/mL, 89.1% had GS 7, and 66.7% had T1 disease. There were no differences in FFP. The 5-year FFP-ASTRO was 85.6% (95% CI, 81.4 to 89.7) with COMBO compared with 82.7% (95% CI, 78.3 to 87.1) with BT (odds ratio [OR], 0.80; 95% CI, 0.51 to 1.26; Greenwood T P = .18). The 5-year FFP-Phoenix was 88.0% (95% CI, 84.2 to 91.9) with COMBO compared with 85.5% (95% CI, 81.3 to 89.6) with BT (OR, 0.80; 95% CI, 0.49 to 1.30; Greenwood T P = .19). There were no differences in the rates of genitourinary (GU) or GI acute toxicities. The 5-year cumulative incidence for late GU/GI grade 2+ toxicity is 42.8% (95% CI, 37.0 to 48.6) for COMBO compared with 25.8% (95% CI, 20.9 to 31.0) for BT ( P < .0001). The 5-year cumulative incidence for late GU/GI grade 3+ toxicity is 8.2% (95% CI, 5.4 to 11.8) compared with 3.8% (95% CI, 2.0 to 6.5; P = .006).CONCLUSION: Compared with BT, COMBO did not improve FFP for prostate cancer but caused greater toxicity. BT alone can be considered as a standard treatment for men with intermediate-risk prostate cancer.